MA26940A1 - Imidazoles substitues servant d'inhibiteurs de tafia - Google Patents

Imidazoles substitues servant d'inhibiteurs de tafia

Info

Publication number: MA26940A1
Authority: MA; Morocco
Prior art keywords: imidazoles; substitutes; serving; tafia inhibitors; tafia
Prior art date: 2000-08-17

Application number

MA27025A

Other languages

English (en)

Inventor

Charlotte Moira Norfo Allerton

Julian Blagg

Mark Edward Bunnage

John Steele

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-17

Filing date

2003-02-04

Publication date

2004-12-20

2000-08-17 Priority claimed from GB0020346A external-priority patent/GB0020346D0/en

2000-11-09 Priority claimed from GB0027409A external-priority patent/GB0027409D0/en

2000-12-04 Priority claimed from GB0029556A external-priority patent/GB0029556D0/en

2003-02-04 Application filed by Pfizer filed Critical Pfizer

2004-12-20 Publication of MA26940A1 publication Critical patent/MA26940A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Surgery (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Ophthalmology & Optometry (AREA)
Pregnancy & Childbirth (AREA)

MA27025A 2000-08-17 2003-02-04 Imidazoles substitues servant d'inhibiteurs de tafia MA26940A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0020346A GB0020346D0 (en)	2000-08-17	2000-08-17	Pharmaceuticals
GB0027409A GB0027409D0 (en)	2000-11-09	2000-11-09	Pharmaceuticals
GB0029556A GB0029556D0 (en)	2000-12-04	2000-12-04	Pharmaceuticals

Publications (1)

Publication Number	Publication Date
MA26940A1 true MA26940A1 (fr)	2004-12-20

Family

ID=27255849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27025A MA26940A1 (fr)	2000-08-17	2003-02-04	Imidazoles substitues servant d'inhibiteurs de tafia

Country Status (38)

Country	Link
EP (1)	EP1311488B1 (fr)
JP (2)	JP4119746B2 (fr)
KR (1)	KR20030022412A (fr)
CN (1)	CN1443173A (fr)
AP (1)	AP1375A (fr)
AR (1)	AR035580A1 (fr)
AT (1)	ATE447557T1 (fr)
AU (1)	AU2001276605A1 (fr)
BG (1)	BG107330A (fr)
BR (1)	BR0113289A (fr)
CA (1)	CA2419633C (fr)
CY (1)	CY1109693T1 (fr)
CZ (1)	CZ2003388A3 (fr)
DE (1)	DE60140368D1 (fr)
DK (1)	DK1311488T3 (fr)
DO (1)	DOP2001000233A (fr)
EA (1)	EA005532B1 (fr)
EE (1)	EE200300070A (fr)
ES (1)	ES2334101T3 (fr)
HR (1)	HRP20030103A2 (fr)
HU (1)	HUP0303763A3 (fr)
IL (1)	IL153225A0 (fr)
IS (1)	IS6638A (fr)
MA (1)	MA26940A1 (fr)
MX (1)	MXPA03001425A (fr)
NO (1)	NO20030706L (fr)
NZ (1)	NZ522823A (fr)
OA (1)	OA12362A (fr)
PA (1)	PA8525401A1 (fr)
PE (1)	PE20020352A1 (fr)
PL (1)	PL361054A1 (fr)
PT (1)	PT1311488E (fr)
SI (1)	SI1311488T1 (fr)
SK (1)	SK1732003A3 (fr)
SV (1)	SV2002000602A (fr)
TN (1)	TNSN01126A1 (fr)
UY (1)	UY26889A1 (fr)
WO (1)	WO2002014285A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103272D0 (sv)	2001-09-28	2001-09-28	Astrazeneca Ab	Chemical compounds
US6713496B2 (en)	2002-01-22	2004-03-30	Pfizer Inc	3-(imidazolyl)-2-alkoxypropanoic acids
OA12756A (en) *	2002-01-22	2006-07-03	Pfizer	3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors.
WO2003061653A1 (fr) *	2002-01-22	2003-07-31	Pfizer Limited	Acides 3-(imidazolyl)-2-aminopropanoiques servant d'inhibiteurs tafia pour traiter des maladies thrombotiques
DE602004024879D1 (de)	2003-04-29	2010-02-11	Univ Zuerich	AN EINEM BIOMOLEKÜL GEBUNDENEN N epsilon- UND/ODER N alpha DERIVATISIERTEM UND ORGANISCH-GESCHÜTZTEM L-HISTIDIN ZUR HOCH-EFFIZIENTER MARKIERUNG MIT (M(H2O)3(CO)3)+ MITTELS FAC KOORDINIERUNG
SE0302853D0 (sv) *	2003-10-29	2003-10-29	Astrazeneca Ab	Chemical compounds
EP1680120A2 (fr) *	2003-11-03	2006-07-19	Probiodrug AG	Combinaisons utiles au traitement de troubles neuronaux
WO2005051384A1 (fr) *	2003-11-25	2005-06-09	Pfizer Limited	Compositions pharmaceutiques stabilisees
CA2604912A1 (fr) *	2005-04-18	2006-10-26	Bayer Schering Pharma Aktiengesellschaft	Utilisation d'inhibiteurs de tafi pour ameliorer la reperfusion myocardique et faciliter la pci
DE102005049385A1 (de) *	2005-10-15	2007-04-19	Sanofi-Aventis Deutschland Gmbh	Imidazolderivate als Inhibitoren von TAFIa
PT2104497E (pt) *	2006-12-06	2015-06-09	Sanofi Sa	Derivados de ureia e sulfamida enquanto inibidores de tafia
WO2009103432A2 (fr) *	2008-02-21	2009-08-27	Sanofi-Aventis	Sondes d’imagerie à liaison covalente
JPWO2010050525A1 (ja) *	2008-10-29	2012-03-29	大正製薬株式会社	ＴＡＦＩａ阻害活性を有する化合物
FR2947266B1 (fr) *	2009-06-26	2011-06-17	Servier Lab	Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2643132T3 (es) *	2010-03-18	2017-11-21	Daiichi Sankyo Company, Limited	Derivado de imidazol cicloalquilo sustituido
WO2011115065A1 (fr)	2010-03-18	2011-09-22	第一三共株式会社	Dérivé d'acide cyclopropanecarboxylique
MX369019B (es) *	2011-05-17	2019-10-24	Pharmasyntez	Compuestos inhibidores de quinasa map p38 como agentes antiadherencias, conjugados con una unidad estructural de polímeros básicos solubles en agua y su uso para el tratamiento o prevención de adherencias en tejidos u órganos.
HRP20180397T1 (hr) *	2011-07-22	2018-05-18	Cambrex Karlskoga Ab	Novi postupci za pripremanje 4-supstituiranih imidazola
WO2013039202A1 (fr) *	2011-09-15	2013-03-21	第一三共株式会社	Nouveau dérivé d'acide acrylique
SG11201509144YA (en)	2013-06-10	2015-12-30	Sanofi Sa	MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI<sb>A</sb>, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
CN108349904B (zh)	2015-10-07	2021-08-31	米托布里奇公司	Ppar激动剂、化合物、药物组合物及其使用方法
FR3046793B1 (fr) *	2016-01-14	2018-01-05	Les Laboratoires Servier	Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN108883094A (zh) *	2016-03-29	2018-11-23	第三共株式会社	炎症性肠病治疗剂
WO2017180818A1 (fr)	2016-04-13	2017-10-19	Mitobridge, Inc.	Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
CN113943255B (zh) *	2020-07-17	2024-08-06	深圳信立泰药业股份有限公司	一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6163661A (ja) *	1984-09-05	1986-04-01	Microbial Chem Res Found	ヒスタジン関連化合物
US5993815A (en) *	1996-11-08	1999-11-30	University Of Vermont	Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) *	1999-05-03	1999-05-03	Astra Ab	New compounds

2001
- 2001-08-08 ES ES01954264T patent/ES2334101T3/es not_active Expired - Lifetime
- 2001-08-08 DK DK01954264T patent/DK1311488T3/da active
- 2001-08-08 OA OA1200300039A patent/OA12362A/fr unknown
- 2001-08-08 AU AU2001276605A patent/AU2001276605A1/en not_active Abandoned
- 2001-08-08 EP EP01954264A patent/EP1311488B1/fr not_active Expired - Lifetime
- 2001-08-08 IL IL15322501A patent/IL153225A0/xx unknown
- 2001-08-08 PT PT01954264T patent/PT1311488E/pt unknown
- 2001-08-08 EE EEP200300070A patent/EE200300070A/xx unknown
- 2001-08-08 EA EA200201239A patent/EA005532B1/ru not_active IP Right Cessation
- 2001-08-08 SI SI200130950T patent/SI1311488T1/sl unknown
- 2001-08-08 HU HU0303763A patent/HUP0303763A3/hu unknown
- 2001-08-08 SK SK173-2003A patent/SK1732003A3/sk unknown
- 2001-08-08 BR BR0113289-0A patent/BR0113289A/pt not_active Application Discontinuation
- 2001-08-08 CZ CZ2003388A patent/CZ2003388A3/cs unknown
- 2001-08-08 KR KR10-2003-7002279A patent/KR20030022412A/ko not_active Ceased
- 2001-08-08 HR HR20030103A patent/HRP20030103A2/hr not_active Application Discontinuation
- 2001-08-08 JP JP2002519428A patent/JP4119746B2/ja not_active Expired - Fee Related
- 2001-08-08 CN CN01813131A patent/CN1443173A/zh active Pending
- 2001-08-08 MX MXPA03001425A patent/MXPA03001425A/es active IP Right Grant
- 2001-08-08 DE DE60140368T patent/DE60140368D1/de not_active Expired - Lifetime
- 2001-08-08 WO PCT/IB2001/001425 patent/WO2002014285A1/fr not_active Ceased
- 2001-08-08 PL PL36105401A patent/PL361054A1/xx not_active Application Discontinuation
- 2001-08-08 CA CA2419633A patent/CA2419633C/fr not_active Expired - Fee Related
- 2001-08-08 NZ NZ522823A patent/NZ522823A/en unknown
- 2001-08-08 AT AT01954264T patent/ATE447557T1/de active
- 2001-08-14 PA PA20018525401A patent/PA8525401A1/es unknown
- 2001-08-15 AR ARP010103900A patent/AR035580A1/es unknown
- 2001-08-15 UY UY26889A patent/UY26889A1/es not_active Application Discontinuation
- 2001-08-15 PE PE2001000815A patent/PE20020352A1/es not_active Application Discontinuation
- 2001-08-16 TN TNTNSN01126A patent/TNSN01126A1/fr unknown
- 2001-08-16 AP APAP/P/2001/002250A patent/AP1375A/en active
- 2001-08-16 SV SV2001000602A patent/SV2002000602A/es unknown
- 2001-11-14 DO DO2001000233A patent/DOP2001000233A/es unknown
2002
- 2002-11-28 BG BG107330A patent/BG107330A/xx unknown
- 2002-11-28 IS IS6638A patent/IS6638A/is unknown
2003
- 2003-02-04 MA MA27025A patent/MA26940A1/fr unknown
- 2003-02-14 NO NO20030706A patent/NO20030706L/no not_active Application Discontinuation
2008
- 2008-02-27 JP JP2008045382A patent/JP4778531B2/ja not_active Expired - Fee Related
2009
- 2009-12-30 CY CY20091101349T patent/CY1109693T1/el unknown

Also Published As

Publication number	Publication date
ATE447557T1 (de)	2009-11-15
CY1109693T1 (el)	2014-08-13
AP2001002250A0 (en)	2001-09-30
HRP20030103A2 (en)	2003-04-30
EA200201239A1 (ru)	2003-08-28
EP1311488A1 (fr)	2003-05-21
EE200300070A (et)	2005-02-15
HUP0303763A3 (en)	2004-06-28
EA005532B1 (ru)	2005-04-28
CN1443173A (zh)	2003-09-17
IS6638A (is)	2002-11-28
UY26889A1 (es)	2002-03-22
BR0113289A (pt)	2003-06-17
CZ2003388A3 (cs)	2004-03-17
CA2419633A1 (fr)	2002-02-21
MXPA03001425A (es)	2003-06-06
IL153225A0 (en)	2003-07-06
SV2002000602A (es)	2002-10-24
ES2334101T3 (es)	2010-03-05
PA8525401A1 (es)	2002-04-25
DE60140368D1 (de)	2009-12-17
EP1311488B1 (fr)	2009-11-04
AU2001276605A1 (en)	2002-02-25
OA12362A (en)	2004-04-07
SK1732003A3 (en)	2004-08-03
WO2002014285A1 (fr)	2002-02-21
TNSN01126A1 (fr)	2005-11-10
AP1375A (en)	2005-03-03
JP2008169224A (ja)	2008-07-24
PT1311488E (pt)	2009-12-30
KR20030022412A (ko)	2003-03-15
DK1311488T3 (da)	2010-01-04
SI1311488T1 (sl)	2010-01-29
NZ522823A (en)	2004-11-26
PL361054A1 (en)	2004-09-20
JP2004506044A (ja)	2004-02-26
NO20030706D0 (no)	2003-02-14
AR035580A1 (es)	2004-06-16
NO20030706L (no)	2003-04-15
BG107330A (en)	2003-06-30
HUP0303763A2 (hu)	2004-04-28
JP4778531B2 (ja)	2011-09-21
CA2419633C (fr)	2011-05-10
PE20020352A1 (es)	2002-05-11
JP4119746B2 (ja)	2008-07-16
DOP2001000233A (es)	2002-05-15

Publication	Publication Date	Title
MA26940A1 (fr)	2004-12-20	Imidazoles substitues servant d'inhibiteurs de tafia
CY2003002I1 (el)	2009-11-04	Συνθεσεις ζιπρασιδονης
EP1147107A4 (fr)	2002-05-22	Inhibiteurs d'angiogenese
AR027896A1 (es)	2003-04-16	Composiciones valdecoxib
DE69928933D1 (de)	2006-01-19	Strahlungshärtbare zusammensetzungen
DZ3347A1 (fr)	2001-11-29	Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
DK1049467T3 (da)	2003-02-10	Celecoxib-sammensætninger
AR023440A1 (es)	2002-09-04	Composiciones antitranspirantes
DE60021018D1 (de)	2005-08-04	Polymerzusammensetzungen
DE69919953D1 (de)	2004-10-14	Funktionelle zusammensetzungen
DE60033373D1 (de)	2007-03-29	Flammgeschützte polyolefinzusammensetzungen
ID29785A (id)	2001-10-11	Komposisi-komposisi sampo
DE60007731D1 (de)	2004-02-19	Schweisshemmende zusammensetzungen
DE69931821D1 (de)	2006-07-20	Wärmehärtbare pulverlack-zusammensetzung
DE69926907D1 (de)	2005-09-29	Bleichungzusammensetzungen
IT1319267B1 (it)	2003-09-26	Apparecchiatura per impedire la sfilacciatura di linee di cuciture.
DE69940932D1 (de)	2009-07-09	Orale Zusammensetzungen mit 8-chloro-6,11-dihydro-11-(4-piperidylene)-5H-benzoÄ5,6Ü-cyclo-heptaÄ1,2-bÜpyridin
DE69905025D1 (de)	2003-02-27	Form vi, 5,6-dichlor-2-(isopropylamino) -1-(beta-l-ribofuranosyl)-1h-benzimidazole
FI981298L (fi)	1999-12-06	Polymeerikoostumukset
ID30320A (id)	2001-11-22	Komposisi-komposisi berpigmen
FR2804049B1 (fr)	2002-04-19	Machine d'usinage perfectionnee
FR2792306B1 (fr)	2001-06-15	Composition derivee de bi26mo10o69
EP1354589A4 (fr)	2004-11-24	Inhibiteurs d'angiogenese
DE60029780D1 (de)	2006-09-14	Biozide zusammensetzungen
ITRM20040312A1 (it)	2004-09-24	Scatola perfezionata per capi d'abbigliamento.